HER2-negative breast cancer
New Strategy Proposed for HR+, HER2– Advanced Breast Cancer
In certain patients with HR+, HER2– advanced breast cancer, switching from an aromatase inhibitor to ...
AUGUST 27, 2025
FDA Approves Truqap With Fulvestrant for Breast Cancer
The FDA approved capivasertib with fulvestrant for adults with HR-positive, HER2-negative locally advanced or ...
NOVEMBER 17, 2023
Adding Palbociclib to Endocrine Therapy Shows No Benefit in Study
There is no benefit to adding palbociclib to endocrine therapy in patients with early hormone receptor ...
MARCH 23, 2022
FDA Approves Talzenna for gBRCAm HER2-Negative Breast Cancer
The FDA approved Talzenna, a poly(adenosine diphosphate–ribose) polymerase inhibitor, for patients with ...
OCTOBER 16, 2018
FDA Approves Kisqali Femara Co-Pack
The co-pack is the first, and only currently available, combination pack with two prescription products for ...
MAY 10, 2017
